Risperidone Long-Acting Injection (Okedi)
Canadian Journal of Health Technologies · 13.05.2026 · 6 (5)
DOI: 10.51731/cjht.2026.1439 ↗Kurz gefasst
Fachartikel in der Zeitschrift Canadian Journal of Health Technologies, online erschienen am 13.05.2026. Verfasst von CDA-AMC.
Abstract (Originalsprache)
Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec. This review assesses risperidone long-acting injection (Okedi), 75 mg or 100 mg, powder for extended-release suspension, intramuscular injection. Indication: The treatment of schizophrenia in adults.
Zitieren
APA
CDA-AMC (2026). Risperidone Long-Acting Injection (Okedi). Canadian Journal of Health Technologies, 6(5). https://doi.org/10.51731/cjht.2026.1439
Vancouver
CDA-AMC. Risperidone Long-Acting Injection (Okedi). Canadian Journal of Health Technologies. 2026;6(5). doi:10.51731/cjht.2026.1439
BibTeX
@article{CDAAMC2026,
author = {CDA-AMC},
title = {Risperidone Long-Acting Injection (Okedi)},
journal = {Canadian Journal of Health Technologies},
year = {2026},
volume = {6},
number = {5},
doi = {10.51731/cjht.2026.1439}
}
EUVIMED